Summary & Overview
HCPCS S3652: Saliva Hormone Test to Assess Preterm Labor Risk
HCPCS Level II code S3652 represents a salivary hormone assay used to assess risk of preterm labor. This code identifies a noninvasive diagnostic laboratory test that measures hormonal biomarkers in saliva to support clinical evaluation of threatened preterm birth. Nationally, such assays are relevant to prenatal care pathways, early risk stratification, and decisions about monitoring and intervention.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage patterns and typical reimbursement considerations across major payers, clinical context on the test’s role in preterm labor risk assessment, and common billing elements tied to HCPCS Level II reporting. The publication outlines where the service is typically provided (outpatient laboratory or obstetrics clinic), what the code denotes, and practical information for coding workflows.
This summary is intended to inform billing, clinical, and policy audiences about the purpose and placement of HCPCS Level II code S3652, relevant payer scope, and the types of insights available in the full publication, such as payer benchmarks, coverage policy summaries, and clinical use cases.
Billing Code Overview
HCPCS Level II code S3652 describes a saliva test for hormone levels to assess preterm labor risk. The service is a diagnostic laboratory test that analyzes salivary biomarkers associated with preterm labor. The typical site of service is outpatient laboratory collection or outpatient obstetrics clinic, where saliva specimens are collected and sent to a lab for analysis.
Service Type: Diagnostic laboratory test
Typical Site of Service: Outpatient laboratory collection or outpatient obstetrics clinic
Clinical & Coding Specifications
Clinical Context
A 29-year-old pregnant patient at 24 weeks' gestation presents to an outpatient maternal-fetal medicine clinic with intermittent uterine cramping and a history of prior spontaneous preterm birth. The clinician orders a salivary hormone test to assess risk factors associated with preterm labor, specifically measuring biomarkers (e.g., cortisol and progesterone ratios) in saliva that may correlate with cervical remodeling and stress-related risk. A saliva specimen is collected in clinic by trained staff using a standardized collection kit, labeled, and sent to an accredited reference laboratory. Results are reviewed by the maternal-fetal medicine specialist during a follow-up visit or via secure patient portal; abnormal results inform enhanced surveillance, possible interventions, or timing of additional diagnostic testing (for example, cervical length ultrasound or fetal fibronectin testing). Typical documentation includes indication, informed consent, collection time, specimen handling, and result interpretation in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard service | Apply when no special modifier applies and service is billed normally |
52 | Reduced services |